Arrowhead announced that it has filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference, or RNAi, therapeutic being developed as a potential treatment for obesity. Arrowhead also plans to file for regulatory clearance before the end of 2024 to initiate a clinical trial for its second obesity candidate, ARO-ALK7.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead granted breakthrough therapy designation for plozasiran by FDA
- Arrowhead to host conference call
- Arrowhead presents new pivotal Phase 3 data from PALISADE study of Plozasiran
- Arrowhead to advance two RNAi-based obesity candidates into clinical studies
- Arrowhead price target lowered to $28 from $31 at Goldman Sachs